NFKB1 and primary cutaneous T-cell non-Hodgkin lymphoma: In agreement with our findings, a clinical study reported that systemic inhibition of NF-κB in CTCL patients induced a skin response in 30.4% of patients, whereas the blood response was mixed [120,121,122] Further, Shin et al. identified ectopic NF-κB signalling in 30.6% of MF patients and that these patients had an aggravated disease course compared to patients without ectopic NF-κB signalling [44].